{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T15:11:25Z","timestamp":1761491485513,"version":"build-2065373602"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005026","name":"Stichting Tegen Kanker","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.coph.2022.102309","type":"journal-article","created":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T05:52:31Z","timestamp":1666849951000},"page":"102309","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["The emerging role of immunotherapy in the treatment of anal cancer"],"prefix":"10.1016","volume":"67","author":[{"given":"Rita","family":"Sa\u00fade-Conde","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Parisi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilio Francesco","family":"Giunta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Meyers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Sclafani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2022.102309_bib1","unstructured":"National Cancer Institute. Surveillance, epidemiology, and end results program. (accessed on 09\/06\/2022) [date unknown],"},{"key":"10.1016\/j.coph.2022.102309_bib2","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.annonc.2021.06.015","article-title":"Anal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up 5 on behalf of the ESMO guidelines committee","volume":"32","author":"Rao","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.coph.2022.102309_bib3","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA A Cancer J Clin"},{"key":"10.1016\/j.coph.2022.102309_bib4","first-page":"924","article-title":"International trends in anal cancer incidence rates","volume":"46","author":"Islami","year":"2017","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.coph.2022.102309_bib5","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/his.12574","article-title":"An update on anal neoplasia","volume":"66","author":"Fl\u00e9jou","year":"2015","journal-title":"Histopathology"},{"key":"10.1016\/j.coph.2022.102309_bib6","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ijc.30716","article-title":"Worldwide burden of cancer attributable to HPV by site, country and HPV type","volume":"141","author":"de Martel","year":"2017","journal-title":"Int J Cancer"},{"key":"10.1016\/j.coph.2022.102309_bib7","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1056\/NEJM199711063371904","article-title":"Sexually transmitted infection as a cause of anal cancer","volume":"337","author":"Frisch","year":"1997","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coph.2022.102309_bib8","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1097\/00126334-200412150-00004","article-title":"HIV-associated anal cancer: has highly active antiretroviral therapy reduced the incidence or improved the outcome?","volume":"37","author":"Bower","year":"2004","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"key":"10.1016\/j.coph.2022.102309_bib9","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S1470-2045(07)70043-8","article-title":"Risk of anogenital cancer after diagnosis of cervical intraepithelial neoplasia: a prospective population-based study","volume":"8","author":"Edgren","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.coph.2022.102309_bib10","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/cncr.20365","article-title":"Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer","volume":"101","author":"Daling","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.coph.2022.102309_bib11","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s12029-015-9790-4","article-title":"Phase II study of capecitabine in substitution of 5-FU in the chemoradiotherapy regimen for patients with localized squamous cell carcinoma of the anal canal","volume":"47","author":"Oliveira","year":"2016","journal-title":"J\u00a0Gastrointest Cancer"},{"key":"10.1016\/j.coph.2022.102309_bib12","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S1470-2045(13)70086-X","article-title":"Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2\u00a0\u00d7 2 factorial trial","volume":"14","author":"James","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.coph.2022.102309_bib13","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/sj.bjc.6605605","article-title":"Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I)","volume":"102","author":"Northover","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.coph.2022.102309_bib14","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0140-6736(97)26003-4","article-title":"Combined radiotherapy and chemotherapy for anal cancer (multiple letters) [12]","volume":"349","author":"Bosset","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2022.102309_bib15","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1200\/JCO.1997.15.5.2040","volume":"15","author":"Bartelink","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.coph.2022.102309_bib16","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1200\/JCO.1996.14.9.2527","article-title":"Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study","volume":"14","author":"Flam","year":"1996","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.coph.2022.102309_bib17","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1002\/bjs.4908","article-title":"Patterns of local disease failure and outcome after salvage surgery in patients with anal cancer","volume":"92","author":"Renehan","year":"2005","journal-title":"Br J Surg"},{"key":"10.1016\/j.coph.2022.102309_bib18","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1071\/SH12070","article-title":"The epidemiology of anal cancer","volume":"9","author":"Grulich","year":"2012","journal-title":"Sex Health"},{"key":"10.1016\/j.coph.2022.102309_bib19","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1159\/000491815","article-title":"New insights into the role of human papillomavirus in anal cancer and anal wart development","volume":"63","author":"Albuquerque","year":"2019","journal-title":"Acta Cytol"},{"key":"10.1016\/j.coph.2022.102309_bib20","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.bbcan.2017.05.001","article-title":"The immune microenvironment and HPV in anal cancer: rationale to complement chemoradiation with immunotherapy","volume":"1868","author":"Martin","year":"2017","journal-title":"Biochim Biophys Acta, Rev Cancer"},{"key":"10.1016\/j.coph.2022.102309_bib21","doi-asserted-by":"crossref","DOI":"10.4161\/21624011.2014.965570","article-title":"Distinct patterns of intratumoral immune cell infiltrates in patients with HPV-associated compared to non-virally induced head and neck squamous cell carcinoma","volume":"4","author":"Partlov\u00e1","year":"2015","journal-title":"OncoImmunology"},{"key":"10.1016\/j.coph.2022.102309_bib22","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1288331","article-title":"Human papilloma virus load and PD-1\/PD-L1, CD8+ and FOXP3 in anal cancer patients treated with chemoradiotherapy: rationale for immunotherapy","volume":"6","author":"Balermpas","year":"2017","journal-title":"OncoImmunology"},{"key":"10.1016\/j.coph.2022.102309_bib23","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/jso.23998","article-title":"Tumor-infiltrating CD8(+) T lymphocytes associated with clinical outcome in anal squamous cell carcinoma","volume":"112","author":"Hu","year":"2015","journal-title":"J\u00a0Surg Oncol"},{"key":"10.1016\/j.coph.2022.102309_bib24","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/bjc.2015.448","article-title":"Tumour-infiltrating lymphocyte scores effectively stratify outcomes over and above p16 post chemo-radiotherapy in anal cancer","volume":"114","author":"Gilbert","year":"2016","journal-title":"Br J Cancer"},{"key":"10.1016\/j.coph.2022.102309_bib25","first-page":"551","article-title":"Biomarkers in immunotherapy-based precision treatments of digestive system tumors","volume":"11","author":"Zeng","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.coph.2022.102309_bib26","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1158\/1541-7786.MCR-17-0060","article-title":"Comprehensive genomic profiling of metastatic squamous cell carcinoma of the anal canal","volume":"15","author":"Morris","year":"2017","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.coph.2022.102309_bib27","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.25109","article-title":"Prevalence of high tumor mutational burden and association with survival in patients with less common solid tumors","volume":"3","author":"Shao","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.coph.2022.102309_bib28","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1158\/1541-7786.MCR-17-0735","article-title":"Landscape of tumor mutation load, mismatch repair deficiency, and PD-L1 expression in a large patient cohort of gastrointestinal cancers","volume":"16","author":"Salem","year":"2018","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.coph.2022.102309_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers12092516","article-title":"Evaluation of PD-L1 expression and HPV genotyping in anal squamous cell carcinoma","volume":"12","author":"Wessely","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.coph.2022.102309_bib30","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S1470-2045(17)30104-3","article-title":"Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study","volume":"18","author":"Morris","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.coph.2022.102309_bib31","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1093\/annonc\/mdx029","article-title":"Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal","volume":"28","author":"Ott","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.coph.2022.102309_sref32","article-title":"Pembrolizumab for advanced anal squamous cell carcinoma (ASCC): results from the multicohort, phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.coph.2022.102309_sref33","first-page":"9","article-title":"Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous cell anal carcinoma: the CARACAS study","author":"Lonardi","year":"2021","journal-title":"J\u00a0Immunother cancer"},{"key":"10.1016\/j.coph.2022.102309_bib34","article-title":"Bintrafusp alfa, a bifunctional fusion protein targeting TGF-\u03b2 and PD-L1, in patients with human papillomavirus-associated malignancies","volume":"8","author":"Strauss","year":"2020","journal-title":"J\u00a0Immunother cancer"},{"key":"10.1016\/j.coph.2022.102309_bib35","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1097\/COC.0000000000000343","article-title":"Programmed cell death-ligand 1 (PD-L1) expression in anal cancer","volume":"41","author":"Govindarajan","year":"2018","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.coph.2022.102309_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/CMAR.S153965","article-title":"Programmed death-ligand 1 expression correlates with diminished CD8+ T cell infiltration and predicts poor prognosis in anal squamous cell carcinoma patients","volume":"10","author":"Zhao","year":"2018","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.coph.2022.102309_bib37","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1038\/modpathol.2015.108","article-title":"Enhanced expression of PD L1 in cervical intraepithelial neoplasia and cervical cancers","volume":"28","author":"Mezache","year":"2015","journal-title":"Mod Pathol"},{"key":"10.1016\/j.coph.2022.102309_bib38","first-page":"157","article-title":"Unique differential expression of PD-L1 in anal squamous cell dysplasia and invasive carcinoma","volume":"97","author":"Bandy","year":"2017","journal-title":"Lab Invest"},{"key":"10.1016\/j.coph.2022.102309_bib39","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s00262-006-0272-1","article-title":"Contribution of the PD-L1\/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion","volume":"56","author":"Blank","year":"2007","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.coph.2022.102309_sref40","doi-asserted-by":"crossref","first-page":"S1170","DOI":"10.1016\/j.annonc.2020.08.2272","article-title":"POD1UM-202: phase II study of retifanlimab in patients (pts) with squamous carcinoma of the anal canal (SCAC) who progressed following platinum-based chemotherapy","volume":"31","author":"Rao","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.coph.2022.102309_sref41","article-title":"Atezolizumab plus modified DCF (docetaxel, cisplatin, and 5-fluorouracil) as first-line treatment for metastatic or locally advanced squamous cell anal carcinoma: a SCARCE-PRODIGE 60 randomized phase II study","volume":"40","author":"Kim","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.coph.2022.102309_bib42","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1158\/1078-0432.CCR-06-1726","article-title":"Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines","volume":"13","author":"Kurai","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.coph.2022.102309_bib43","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006504","article-title":"Up-regulation of PD-L1, Ido, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells","volume":"5","author":"Spranger","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coph.2022.102309_bib44","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.4_suppl.005","article-title":"Extensive molecular profiling of squamous cell anal carcinoma in a phase 2 trial population: translational analyses of the \u201cCARACAS\u201d study","volume":"40","author":"Prete","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.coph.2022.102309_bib45","doi-asserted-by":"crossref","first-page":"753","DOI":"10.5306\/wjco.v5.i4.753","article-title":"Role of IL-10 and TGF-\u03b21 in local immunosuppression in HPV-associated cervical neoplasia","volume":"5","author":"Torres-Poveda","year":"2014","journal-title":"World J Clin Oncol"},{"key":"10.1016\/j.coph.2022.102309_bib46","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/nrclinonc.2018.9","article-title":"Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa","volume":"15","author":"Khan","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.coph.2022.102309_bib47","doi-asserted-by":"crossref","first-page":"S412","DOI":"10.1016\/j.annonc.2020.08.514","article-title":"403MO Atezolizumab in combination with bevacizumab for patients with unresectable\/metastatic anal cancer","volume":"31","author":"Morris","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.coph.2022.102309_sref48","doi-asserted-by":"crossref","first-page":"S829","DOI":"10.1016\/j.annonc.2021.08.1342","article-title":"957O Long-term follow-up of patients (pts) with human papillomavirus (HPV)\u2013associated malignancies treated with bintrafusp alfa, a bifunctional fusion protein targeting TGF-\u03b2 and PD-L1","volume":"32","author":"Strauss","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.coph.2022.102309_sref49","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.2501","article-title":"Phase II evaluation of the triple combination of PDS0101, M9241, and bintrafusp alfa in patients with HPV 16 positive malignancies","volume":"39","author":"Strauss","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.coph.2022.102309_sref50","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1200\/JCO.18.02424","article-title":"T-cell receptor gene therapy for human papillomavirus-associated epithelial cancers: a first-in-human, phase I\/II study","volume":"37","author":"Doran","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.coph.2022.102309_sref51","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/s41591-020-01225-1","article-title":"TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers","volume":"27","author":"Nagarsheth","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.coph.2022.102309_bib52","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.18632\/oncotarget.27536","article-title":"A\u00a0phase II study of axalimogene filolisbac for patients with previously treated, unresectable, persistent\/recurrent loco-regional or metastatic anal cancer","volume":"11","author":"Eng","year":"2020","journal-title":"Oncotarget"},{"key":"10.1016\/j.coph.2022.102309_bib53","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1001\/jamaoncol.2018.4051","article-title":"Combining immune checkpoint blockade and tumor-specific vaccine for patients with incurable human papillomavirus 16-related cancer A phase 2 clinical trial","volume":"5","author":"Massarelli","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.coph.2022.102309_bib54","article-title":"ISA101 and nivolumab for HPV-16+ cancer: updated clinical efficacy and immune correlates of response","volume":"10","author":"Sousa","year":"2022","journal-title":"J\u00a0Immunother Cancer"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489222001369?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489222001369?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T06:57:39Z","timestamp":1761461859000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489222001369"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":54,"alternative-id":["S1471489222001369"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2022.102309","relation":{},"ISSN":["1471-4892"],"issn-type":[{"type":"print","value":"1471-4892"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The emerging role of immunotherapy in the treatment of anal cancer","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2022.102309","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102309"}}